In most myeloma patients, the glomeruli function normally allows only the small molecular weight proteins, such as light chains, to filter into the urine.

Bisphosphonates are useful for slowing or reversing the osteopenia that is common in myeloma patients.

In multiple myeloma patients, concomitant use with zoledronic acid may lead to increased incidence of renal dysfunction.

In an additional eight myeloma patients, tumors were shrunk by more than 50 percent, Dr. Salmon said.

Her experience is typical of many multiple myeloma patients.

Conversely, urine concentrations of free light chains could increase if renal function improved in a multiple myeloma patient receiving treatment.

The organization helps myeloma patients and raises awareness about this rare form of cancer.

One study on multiple myeloma patients permitted to identified a selective up-regulation of miR-32 and the miR-17-92 cluster.

Since then, many studies have shown that thalidomide, in combination with dexamethasone, has increased the survival of multiple myeloma patients.

Neilson's disease is an aggressive one; the five-year survival rate for multiple myeloma patients treated only with chemotherapy is 29 percent.